Published in Lancet on March 13, 1999
The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS (2010) 5.85
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med (2003) 4.57
Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ (2003) 3.19
Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J Virol (2004) 3.13
Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood (2006) 2.90
Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med (2003) 2.81
Molecular characterization of Cryptosporidium isolates obtained from human immunodeficiency virus-infected individuals living in Switzerland, Kenya, and the United States. J Clin Microbiol (2000) 2.32
Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected drug users. J Gen Intern Med (2003) 2.18
Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. Clin Infect Dis (2011) 2.15
Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS (2011) 2.04
Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med (2006) 1.85
The epidemiological impact of antiretroviral use predicted by mathematical models: a review. Emerg Themes Epidemiol (2005) 1.76
Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. J Virol (2005) 1.68
Impaired response to HAART in HIV-infected individuals with high autonomic nervous system activity. Proc Natl Acad Sci U S A (2001) 1.68
Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection. Clin Infect Dis (2011) 1.64
Is average adherence to HIV antiretroviral therapy enough? J Gen Intern Med (2002) 1.58
Survival, plasma HIV-1 RNA concentrations and drug resistance in HIV-1-infected Haitian adolescents and young adults on antiretrovirals. Bull World Health Organ (2008) 1.49
Effectiveness of highly active antiretroviral therapy among HIV-1 infected women. J Epidemiol Community Health (2002) 1.42
The Direct Medical Costs of Late Presentation (<350/mm) of HIV Infection over a 15-Year Period. AIDS Res Treat (2011) 1.41
The pulmonary physician in critical care * Illustrative case 5: HIV associated pneumonia. Thorax (2003) 1.40
Incidence of virological failure and major regimen change of initial combination antiretroviral therapy in the Latin America and the Caribbean: an observational cohort study. Lancet HIV (2015) 1.38
Provider-focused intervention increases adherence-related dialogue but does not improve antiretroviral therapy adherence in persons with HIV. J Acquir Immune Defic Syndr (2010) 1.38
4'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro. Antimicrob Agents Chemother (2001) 1.35
Incarceration predicts virologic failure for HIV-infected injection drug users receiving antiretroviral therapy. Clin Infect Dis (2011) 1.29
Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption. PLoS One (2011) 1.24
Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy. BMJ (2002) 1.21
Membrane-anchored peptide inhibits human immunodeficiency virus entry. J Virol (2001) 1.20
St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol (2002) 1.18
Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection. AIDS Res Hum Retroviruses (2008) 1.15
Short-term discontinuation of HAART regimens more common in vulnerable patient populations. AIDS Res Hum Retroviruses (2008) 1.15
The role of therapeutic drug monitoring in treatment of HIV infection. Br J Clin Pharmacol (2001) 1.14
In vitro hypersusceptibility of human immunodeficiency virus type 1 subtype C protease to lopinavir. Antimicrob Agents Chemother (2003) 1.14
The role of antigenic stimulation and cytotoxic T cell activity in regulating the long-term immunopathogenesis of HIV: mechanisms and clinical implications. Proc Biol Sci (2001) 1.14
Adverse drug reactions of Highly Active Antiretroviral Therapy (HAART) in HIV infected patients at the General Hospital, Douala, Cameroon: a cross sectional study. Pan Afr Med J (2012) 1.08
Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: A meta-analysis: Meta-analysis of IL28B. Hepat Mon (2011) 1.06
Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir. Antimicrob Agents Chemother (2002) 1.05
Performance characteristics of the QUANTIPLEX HIV-1 RNA 3.0 assay for detection and quantitation of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (2000) 1.05
Magnitude and determinants of nonadherence and nonreadiness to highly active antiretroviral therapy among people living with HIV/AIDS in Northwest Ethiopia: a cross-sectional study. AIDS Res Ther (2010) 1.05
Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1. J Virol (2005) 1.05
In vitro human immunodeficiency virus eradication by autologous CD8(+) T cells expanded with inactivated-virus-pulsed dendritic cells. J Virol (2001) 1.04
Viral evolution in response to the broad-based retroviral protease inhibitor TL-3. J Virol (2001) 1.03
Evolution and recombination of genes encoding HIV-1 drug resistance and tropism during antiretroviral therapy. Virology (2010) 1.02
Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007. PLoS One (2009) 1.01
Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (2004) 1.01
Causality, mediation and time: a dynamic viewpoint. J R Stat Soc Ser A Stat Soc (2012) 1.00
Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users. J Urban Health (2003) 0.98
Highly active antiretroviral therapy restores in vitro mitogen and antigen-specific T-lymphocyte responses in HIV-1 perinatally infected children despite virological failure. Clin Exp Immunol (2002) 0.97
Perinatal depressive symptoms in HIV-infected versus HIV-uninfected women: a prospective study from preconception to postpartum. J Womens Health (Larchmt) (2011) 0.97
Prevalence of drug resistance mutations and HIV type 1 subtypes in an HIV type 1-infected cohort in rural Tanzania. AIDS Res Hum Retroviruses (2013) 0.97
The changing epidemiology of HIV infection: new challenges for HIV palliative care. J R Soc Med (2001) 0.95
Incidence and determinants of new AIDS-defining illnesses after HAART initiation in a Senegalese cohort. BMC Infect Dis (2010) 0.95
Predictors of highly active antiretroviral therapy utilization for behaviorally HIV-1-infected youth: impact of adult versus pediatric clinical care site. J Adolesc Health (2011) 0.95
Adherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort Study. PLoS One (2013) 0.95
Changes in first-line cART regimens and short-term clinical outcome between 1996 and 2010 in The Netherlands. PLoS One (2013) 0.94
Early severe morbidity and resource utilization in South African adults on antiretroviral therapy. BMC Infect Dis (2009) 0.93
The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach. HIV Med (2007) 0.92
Prevalence of human immunodeficiency virus drug resistance mutations and subtypes in drug-naive, infected individuals in the army health service of Rio de Janeiro, Brazil. J Clin Microbiol (2004) 0.91
Persistence of transmitted HIV-1 drug resistance mutations associated with fitness costs and viral genetic backgrounds. PLoS Pathog (2015) 0.91
Treatment acceptance and adherence in HIV disease: patient identity and the perceived impact of physician-patient communication. Patient Prefer Adherence (2012) 0.90
Composition and function of T cell subpopulations are slow to change despite effective antiretroviral treatment of HIV disease. PLoS One (2014) 0.90
Variant human immunodeficiency virus type 1 proteases and response to combination therapy including a protease inhibitor. Antimicrob Agents Chemother (2001) 0.90
Interplay between single resistance-associated mutations in the HIV-1 protease and viral infectivity, protease activity, and inhibitor sensitivity. Antimicrob Agents Chemother (2011) 0.90
The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects. Br J Clin Pharmacol (2002) 0.87
Prevalence of protease and reverse transcriptase drug resistance mutations over time in drug-naïve human immunodeficiency virus type 1-positive individuals in Rio de Janeiro, Brazil. Antimicrob Agents Chemother (2002) 0.87
The cost-effectiveness of counseling strategies to improve adherence to highly active antiretroviral therapy among men who have sex with men. Med Decis Making (2008) 0.87
The interplay between CD4 cell count, viral load suppression and duration of antiretroviral therapy on mortality in a resource-limited setting. Trop Med Int Health (2013) 0.86
Bimodal virological response to antiretroviral therapy for HIV infection: an application using a mixture model with left censoring. J Epidemiol Community Health (2006) 0.86
A comparison of initial antiretroviral therapy in the Swiss HIV Cohort Study and the recommendations of the International AIDS Society-USA. PLoS One (2011) 0.86
Using mathematical modeling and control to develop structured treatment interruption strategies for HIV infection. Drug Alcohol Depend (2007) 0.86
Direct effect of human immunodeficiency virus protease inhibitors on neutrophil function and apoptosis via calpain inhibition. Clin Vaccine Immunol (2007) 0.85
A double-blind, adjuvant-controlled trial of human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) monotherapy in asymptomatic, HIV-1-infected thai subjects with CD4-cell counts of >300. Clin Diagn Lab Immunol (2000) 0.85
[Risk factors associated with virologic failure in HIV- infected patients receiving antiretroviral therapy at a public hospital in Peru]. Rev Chilena Infectol (2013) 0.85
Elevated CD8 counts during HAART are associated with HIV virologic treatment failure. J Acquir Immune Defic Syndr (2011) 0.84
Soluble urokinase plasminogen activator receptor (suPAR) is associated with metabolic changes in HIV-1-infected Africans: a prospective study. Inflammation (2012) 0.83
Toward the development of a virus-cell-based assay for the discovery of novel compounds against human immunodeficiency virus type 1. Antimicrob Agents Chemother (2003) 0.83
Results of antiretroviral treatment interruption and intensification in advanced multi-drug resistant HIV infection from the OPTIMA trial. PLoS One (2011) 0.82
Clinical, immunological and virological evolution in patients with CD4 T-cell count above 500/mm3: is there a benefit to treat with highly active antiretroviral therapy (HAART)? Eur J Epidemiol (2004) 0.82
Clinical evaluation of a dried blood spot assay for atazanavir. Antimicrob Agents Chemother (2010) 0.81
Physical activity and health outcomes among HIV-infected men who have sex with men: a longitudinal mediational analysis. Ann Behav Med (2013) 0.81
High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis. J Clin Microbiol (2003) 0.81
Rates of inappropriate antiretroviral prescription among injection drug users. Harm Reduct J (2007) 0.81
Health literacy in HIV treatment: accurate understanding of key biological treatment principles is not required for good ART adherence. AIDS Behav (2015) 0.80
Causes of Death among AIDS Patients after Introduction of Free Combination Antiretroviral Therapy (cART) in Three Chinese Provinces, 2010-2011. PLoS One (2015) 0.80
Lower CD4 cell count and higher virus load, but not antiretroviral drug resistance, are associated with AIDS-defining events and mortality: an ACTG Longitudinal Linked Randomized Trials (ALLRT) analysis. HIV Clin Trials (2011) 0.80
The role of clinical pharmacology in optimizing antiretroviral therapy. Br J Clin Pharmacol (2003) 0.79
Can we believe the DAGs? A comment on the relationship between causal DAGs and mechanisms. Stat Methods Med Res (2014) 0.78
Epigenetic analysis of HIV-1 proviral genomes from infected individuals: predominance of unmethylated CpG's. Virology (2013) 0.78
The Clinical Implications of Reduced Viral Fitness. Curr Infect Dis Rep (2004) 0.78
Risk factors for short-term virologic outcomes among HIV-infected patients undergoing regimen switch of combination antiretroviral therapy. AIDS Res Hum Retroviruses (2012) 0.78
Quantitative immunoassay to measure plasma and intracellular atazanavir levels: analysis of drug accumulation in cultured T cells. Antimicrob Agents Chemother (2006) 0.78
Steps towards preventive HIV treatment in Fujian, China: problems identified via an assessment of initial antiretroviral therapy provision. PLoS One (2013) 0.78
Factors linked to transitions in adherence to antiretroviral therapy among HIV-infected illicit drug users in a Canadian setting. AIDS Care (2015) 0.78
Nelfinavir and non-nucleoside reverse transcriptase inhibitor-based salvage regimens in heavily HIV pretreated patients. Can J Infect Dis (2003) 0.77
Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742. Antimicrob Agents Chemother (2008) 0.77
Therapeutic drug monitoring in human immunodeficiency virus/acquired immunodeficiency syndrome. Quo vadis? Arch Pathol Lab Med (2003) 0.77
Factors associated with initiation of antiretroviral therapy among HIV-positive people who use injection drugs in a Canadian setting. AIDS (2016) 0.76
Mathematical modeling of HIV prevention measures including pre-exposure prophylaxis on HIV incidence in South Korea. PLoS One (2014) 0.76
Management of HIV-infected Patients with Multidrug-resistant Virus. Curr Infect Dis Rep (2002) 0.76
The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med (2001) 37.70
Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ (2001) 20.65
The hazards of scoring the quality of clinical trials for meta-analysis. JAMA (1999) 17.00
Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol (2001) 12.72
Misleading meta-analysis. BMJ (1995) 11.94
Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol (2000) 7.95
Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. BMJ (2001) 7.13
Molecular beacon sequence analysis for detecting drug resistance in Mycobacterium tuberculosis. Nat Biotechnol (1998) 6.59
Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother (1994) 6.39
Who benefits from medical interventions? BMJ (1994) 5.58
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS (2001) 5.52
Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet (2000) 5.49
Molecular approach to identifying route of transmission of tuberculosis in the community. Lancet (1993) 4.96
Early enteral feeding versus "nil by mouth" after gastrointestinal surgery: systematic review and meta-analysis of controlled trials. BMJ (2001) 4.47
Vitellogenin in Xenopus laevis is encoded in a small family of genes. Cell (1979) 4.44
Disseminated "Mycobacterium genavense" infection in patients with AIDS. Lancet (1992) 4.42
Socioeconomic differentials in wealth and health. BMJ (1993) 4.32
Effects of antibiotic treatment in the subset of common-cold patients who have bacteria in nasopharyngeal secretions. Lancet (1996) 4.22
Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants. J Virol (1999) 4.16
Rapid Mycobacterium species assignment and unambiguous identification of mutations associated with antimicrobial resistance in Mycobacterium tuberculosis by automated DNA sequencing. Arch Pathol Lab Med (1995) 4.10
Diagnostic performance of amplified Mycobacterium tuberculosis direct test with cerebrospinal fluid, other nonrespiratory, and respiratory specimens. J Clin Microbiol (1996) 3.85
Direct detection of Mycobacterium tuberculosis complex in respiratory specimens by a target-amplified test system. J Clin Microbiol (1994) 3.81
Brief report: disseminated osteomyelitis from Mycobacterium ulcerans after a snakebite. N Engl J Med (1993) 3.75
Magnesium and myocardial infarction. Lancet (1994) 3.74
Secular trends of tuberculosis in western Europe. Bull World Health Organ (1993) 3.67
Role of Staphylococcus aureus coagulase and clumping factor in pathogenesis of experimental endocarditis. Infect Immun (1995) 3.65
Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapid susceptibility testing. Antimicrob Agents Chemother (2000) 3.56
Grey literature in meta-analyses of randomized trials of health care interventions. Cochrane Database Syst Rev (2007) 3.51
HIV and male circumcision--a systematic review with assessment of the quality of studies. Lancet Infect Dis (2005) 3.49
Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS (1997) 3.42
Reporting on quality of life in randomised controlled trials: bibliographic study. BMJ (1998) 3.37
AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA (1999) 3.34
Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technol Assess (2001) 3.32
Turnover of CD4+ and CD8+ T lymphocytes in HIV-1 infection as measured by Ki-67 antigen. J Exp Med (1998) 3.24
A novel insertion element from Mycobacterium avium, IS1245, is a specific target for analysis of strain relatedness. J Clin Microbiol (1995) 3.20
Smoking and health promotion in Nazi Germany. J Epidemiol Community Health (1994) 3.20
Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation (1999) 3.16
Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations. Antimicrob Agents Chemother (1997) 3.05
Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS (1999) 3.04
Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci U S A (2003) 2.95
HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA (2001) 2.95
Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS (2002) 2.90
Cardiac septal and valvular dysmorphogenesis in mice heterozygous for mutations in the homeobox gene Nkx2-5. Circ Res (2000) 2.82
Do all men attending departments of genitourinary medicine need to be screened for non-gonococcal urethritis? Int J STD AIDS (2002) 2.81
Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections. J Infect Dis (1987) 2.71
Outbreak of Enterobacter cloacae related to understaffing, overcrowding, and poor hygiene practices. Infect Control Hosp Epidemiol (1999) 2.68
Isolation and characterization of a unique group of slowly growing mycobacteria: description of Mycobacterium lentiflavum sp. nov. J Clin Microbiol (1996) 2.66
Funding clinical research. Lancet (1999) 2.63
Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis (1994) 2.61
Crystal structure of GyrA intein from Mycobacterium xenopi reveals structural basis of protein splicing. Nat Struct Biol (1998) 2.59
Comparison of high-pressure liquid chromatography and bioassay for determination of ciprofloxacin in serum and urine. Antimicrob Agents Chemother (1985) 2.55
Role of embB in natural and acquired resistance to ethambutol in mycobacteria. Antimicrob Agents Chemother (1997) 2.53
Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther (2007) 2.48
HIV treatment failure: testing for HIV resistance in clinical practice. Science (1998) 2.46
Nosocomial pneumonia in mechanically ventilated patients receiving antacid, ranitidine, or sucralfate as prophylaxis for stress ulcer. A randomized controlled trial. Ann Intern Med (1994) 2.45
Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS (2001) 2.42
Primary pulmonary hypertension in HIV infection. Chest (1991) 2.40
Vitellogenesis and the vitellogenin gene family. Science (1981) 2.39
The causes and effects of socio-demographic exclusions from clinical trials. Health Technol Assess (2005) 2.38
The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med (2006) 2.38
The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics. Soz Praventivmed (1994) 2.38
Genital Chlamydia trachomatis infections in Uppsala County, Sweden, 1985-1993: declining rates for how much longer? Sex Transm Dis (1995) 2.36
Commentary: understanding it all--health, meta-theories, and mortality trends. BMJ (1997) 2.35
Successful single-dose amoxicillin prophylaxis against experimental streptococcal endocarditis: evidence for two mechanisms of protection. J Infect Dis (1983) 2.35
Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med (1999) 2.35
16S rRNA sequence diversity in Mycobacterium celatum strains caused by presence of two different copies of 16S rRNA gene. J Clin Microbiol (1998) 2.33
Male circumcision for prevention of heterosexual acquisition of HIV in men. Cochrane Database Syst Rev (2003) 2.32
Molecular characterization of Cryptosporidium isolates obtained from human immunodeficiency virus-infected individuals living in Switzerland, Kenya, and the United States. J Clin Microbiol (2000) 2.32
Are randomised controlled trials in the BMJ different? BMJ (2001) 2.26
Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. Antimicrob Agents Chemother (1985) 2.25